Next Science : 2023 Annual Report

TABLE OF

CONTENTS

1.	OUR MISSION	1
2.	PATIENT CASE STUDY	3
3.	PHYSICIAN TESTIMONIALS	5
4.	PRODUCT SHOWCASE	7
5.	COLLAGEN AND DME (DURABLE MEDICAL EQUIPMENT) DISTRIBUTION	10
6.	RESEARCH & DEVELOPMENT	11
7.	CHAIR MESSAGE	13
8.	CEO MESSAGE	15
9.	DIRECTORS' REPORT	19
10.	LEAD AUDITORS INDEPENDENCE DECLARATION	48
11.	CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	49
12.	CONSOLIDATED STATEMENT OF FINANCIAL POSITION	50
13.	CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	51
14.	CONSOLIDATED STATEMENT OF CASH FLOWS	53
15.	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	54
16.	DIRECTORS' DECLARATION	101
17.	INDEPENDENT AUDITOR'S REPORT	102
18.	INVESTOR INFORMATION	106
19.	CORPORATE DIRECTORY	109

OU

1	Annual Report 2023

R MISSION

Next Science strives to significantly improve patient outcomes, elevate physician efficacy, and create value within the overall healthcare system through relentless innovation and commitment to education and research on biofilm elimination, infection prevention, and treatments for inflammatory diseases.

2	Annual Report 2023

PATIENT CASE

STUDY

Acute Septic Arthritic Knee

Read the full report

by Dr. Jon Minter

The patient, an 81-year-old male presented to the emergency room 11 days post-operatively. He had undergone a revision Total Knee Arthroplasty (TKA) due to an unstable knee and on admission complained of knee pain, mental confusion, atrial fibrillation, elevated liver enzymes, inability to stand, and urinary retention.

Aspiration of the knee was conducted and bacteria known as Klebsiella Pneumonia was found. Investigation into the source of the infection identified the cause as an infected pacemaker. Given the patients severely declining health, the decision was made to use arthroscopic lavage to treat the infection as a temporising measure.

Results

Arthroscopic lavage was performed using one litre of saline and two litres of XPERIENCETM. The patient was placed on an antibiotic regimen and the infected pacemaker was replaced during hospitalisation.

At one year follow up, the patient is fully healed and did not suffer any recurence of knee symptoms.

3	Annual Report 2023

#NEXTSCIENCEHEALS

View the full poster by Dr. Mark Melin

Intervention in Chronic Wound

Part of a 3-patient pilot study, a 76-year-old female patient presented with thrombocytosis from a chronic, non-healing wound that was resistant to other therapies. The wound was appropriately debrided, soaked in hypochlorous acid, BLASTX applied, and covered with foam dressing with compression socks.

Results

The patient was monitored at 8 weeks and 16 weeks for signs of healing. By the 16-week mark, the wound was fully healed.

TREATMENT TIMELINE

BLASTX Initiated	4-WeekFollow-up	Wound Closed
11/30/22	12/28/22	3/23/2023
	4	Annual Report 2023

Dr. Matthew Regulsky

Podiatric Surgeon

• I have used this product in probably a million applications and we're seeing really good results using BLASTX powered by the XBIOTM Technology. We have two randomised control trials to show that when you use that, with the Prepare the RepairTM Paradigm, you can have tremendous amount of healing rates. The death rate from any chronic wound is about 30%, diabetic wounds are about 50% because of all of the inflammation and the complexity of the wounds - my own father suffered from a diabetic foot wound and I had to cut off half of my own father's foot. So, I'm passionate about
  the evidence, I'm passionate about the science, and I'm passionate about the results."

PHYSICIAN

TESTIMONIALS

5	Annual Report 2023

#NEXTSCIENCEHEALS

Dr. Ravi K. Bashyal

Orthopedic Surgeon

"As a hip and knee replacement surgeon, my most feared post-op complication is infection. Patients undergoing elective and routine hip or knee replacement are at risk for infection, but it is not their expectation that this will occur. Further, if an infection does occur in a hip or knee replacement, it is a serious complication that always requires surgery to address. In even the most benign circumstance, an infected prosthesis requires at least one repeat operation and many weeks of IV antibiotics - more serious cases may require multiple staged operations, each with likely worse functional final outcomes. Anything I can do to prevent this devastating complication from occurring is of great interest to me. Routine use of XPERIENCETM has been shown to dramatically lower this risk, and has been a game changer in my practice. For over the past two years and over 1000 cases, I have had ZERO infections. There is a multifactorial approach to this, but XPERIENCETM is a big part of this formula. I visualise this product as a paradigm shifting gamechanger. If we can educate and inform the surgical community effectively, it has an opportunity to change standard of care practices in surgery. "

6	Annual Report 2023

PRODUCT

SHOWCASE

In April 2021, XPERIENCETM Advanced Surgical Irrigation received FDA clearance to be sold as a medical device in the United States. This non- toxic technology does not need to be rinsed from the surgical site after closure, offering up to five hours of protection as the solution dilutes in the body, helping to prevent surgical site and post-operative infection.

XPERIENCETM is designed for use in virtually every open orthopedic surgical case, with an initial focus on shoulder, hip, knee, trauma and podiatry.

7	Annual Report 2023